Cancer Network Staff

TALAPRO-3 trial findings support the regulatory decision for the talazoparib-based regimen in HRR-altered metastatic castration resistant prostate cancer.

The FDA has accepted the new drug application for daraxonrasib in metastatic pancreatic ductal adenocarcinoma based on results from the phase 3 RASolute 302 study.

Data from the phase 3 MonumenTAL-6 trial demonstrate the potential to target BCMA and GPRC5D simultaneously in multiple myeloma care.

Carlos Silva Rondon, MD, of Moffitt Cancer Center discussed factors guiding selection between CAR T therapy or bispecific antibodies in follicular lymphoma.

Fast track designation supports pelareorep's development for anal cancer that progresses after first-line checkpoint inhibitor-based therapy.

Investigators will evaluate carotuximab plus radium-223 to overcome treatment resistance in metastatic CRPC with bone metastases.

Updated phase 3 HARMONi trial data show ivonescimab plus chemotherapy improves overall survival in Western and Asian EGFR-mutant NSCLC groups.

Exploratory data showed that serplulimab maintenance or continuation beyond initial progression may yield incremental survival benefits in ES-SCLC.

A 10-year analysis of 3477 patients found low prostate cancer–specific mortality with focal high-intensity focused ultrasound or cryotherapy for nonmetastatic disease.

A peptide vaccine targeting KRAS variants was safe and produced durable T-cell responses in individuals with hereditary predisposition for pancreatic ductal adenocarcinoma.

Patients with a multiple myeloma relapse within 36 months of up-front quadruplet therapy and transplantation should be prioritized for immunotherapy, said Gayathri Ravi, MD.

Traditional acupuncture plus auricular acupressure improved overall quality of life among patients with HNSCC undergoing radiotherapy.

Data from the phase 3 ENDURANCE trial challenge the assumption that a longer duration of therapy is likely to better multiple myeloma care.

Adjuvant atezolizumab nearly doubled disease-free survival in patients with ctDNA-positive muscle-invasive bladder cancer in the phase 3 IMvigor011 trial.

In a phase 1 trial, englumafusp alfa plus glofitamab produced a 68.7% overall response rate in heavily pretreated aggressive B-cell non-Hodgkin lymphoma.

Phase 3 data may support orelabrutinib as a safe and effective option for patients with treatment-naïve CLL or SLL.

The phase 3 KEYNOTE-C93 trial met its primary end point of PFS with pembrolizumab monotherapy vs chemotherapy in dMMR advanced or recurrent endometrial cancer.

Dosing has resumed in the INVINCIBLE-4 trial of INT230-6 plus standard therapy in early-stage triple-negative breast cancer.

Data from the phase 3 OptiTROP-Lung06 trial also showed a positive trend in overall survival with sac-TMT plus pembrolizumab in patients with NSCLC.

The FDA closed out its manufacturing inspection tied to the third complete response letter for rivoceranib/camrelizumab in unresectable HCC.

The FDA has approved the gedatolisib combination for HR+/HER2– PIK3CA wild-type advanced breast cancer post-CDK4/6i, based on the phase 3 VIKTORIA-1 trial.

Agenus is halting financial support for the phase 3 BATTMAN trial in late-line metastatic MSS colorectal cancer to prioritize neoadjuvant development of the same regimen.

Data from the phase 2 RECLAIM trial demonstrate the feasibility of a multimodal strategy in a patient population with limited therapeutic options.

Interim data from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab monotherapy in dMMR/MSI-H locally advanced rectal cancer.

The trial will confirm findings from the phase 3 IT-MATTERS study subgroup with newly diagnosed head and neck cancer who received leukocyte interleukin.

The approval of Orca-T validates many years of work dedicated to manipulating the graft to improve outcomes among patients undergoing allogeneic transplant.

ARTEMIS-008 is the first phase 3 trial to show positive overall survival data for a B7-H3–targeted antibody-drug conjugate in any tumor type.

The FDA has issued a third CRL for the combination based on manufacturing site deficiencies associated with the new drug application.

Miguel A. Materin, MD, discussed insights on multidisciplinary care, intra-arterial chemotherapy, and the evolving landscape of uveal melanoma treatments.

Ateganosine plus cemiplimab showed an acceptable safety profile among patients with third-line NSCLC in the phase 2 THIO-101 trial.